Xygrel As Tab

Xygrel As Tab is a dual antiplatelet therapy (DAPT) formulation designed to prevent blood clots in patients at risk of heart attack, stroke, or other cardiovascular events. This combination therapy is widely prescribed for individuals with acute coronary syndrome (ACS), a history of heart attack, or those undergoing percutaneous coronary intervention (PCI).

• Aspirin 75 MG – A low-dose non-steroidal anti-inflammatory drug (NSAID) that irreversibly inhibits platelet aggregation, reducing the risk of clot formation. It is a cornerstone of cardiovascular preventive therapy.

• Ticagrelor 90 MG – A P2Y12 receptor inhibitor that prevents platelets from sticking together, offering potent antiplatelet activity to further reduce the risk of thrombotic events.

Together, Aspirin and Ticagrelor provide synergistic platelet inhibition, significantly reducing the risk of heart attacks, strokes, and other serious cardiovascular complications. This combination is particularly beneficial for patients who have unstable angina, myocardial infarction (MI), or stent placement and require continuous platelet suppression to maintain cardiovascular health.